AIM ImmunoTech Inc. (AIM) Stock: Here’s Why It’s Falling

Biotech Stocks With Potential!

AIM ImmunoTech Inc. (AIM) is trending down in the market today. The company, one that is focused in the biotech space, is currently trading at $0.55 after a move down of -8.76% so far in today’s session. When it comes to biotechnology companies, there are several aspects that have the ability to cause price movement in the market. News is one of the most common reasons for movement. Here are the most recent stories centered around AIM:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Sep-25-19 09:50AM AIM ImmunoTech, Inc. Announces Pricing of $8 Million Public Offering
Sep-24-19 06:30AM AIM ImmunoTech Inc. Announces a Second DoD Award, This One of $8.3 Million, to Fund Phase 2 Clinical Trial to Study Ampligen as Part of a New Treatment for Brain-Metastatic Breast Cancer at the Moffitt Cancer Center
06:00AM AIM ImmunoTechs Ampligen Receives Clearance from FDA for Exportation to Argentina for the Treatment of Severe Chronic Fatigue Syndrome
Sep-19-19 08:43AM AIM ImmunoTech Shares Spike Up 90% After $6.42M ‘Breakthrough Award’
06:50AM AIM ImmunoTech Inc. Announces the U.S. Department of Defenses Award of $6.42M to Roswell Park Comprehensive Cancer Center to Study Ampligen as Part of a New Treatment of Brain-Metastatic Breast Cancer

However, any time investors are making a decision to invest, investors should take a look at much more than just news, this is especially the case in the highly speculative biotech industry. Here’s what’s happening with AIM ImmunoTech Inc..

The Performance That We’ve Seen From AIM

Although a move toward the top in a single session, like the fall that we’re seeing from AIM ImmunoTech Inc. may cause fear in some investors, a single session decline alone should not be the reason for a decision to, or not to, invest in a stock. It’s always smart to dig into trends experienced by the stock further out than a single trading session. In the case of AIM, below are the returns that investors have experienced:

  • Past 7 Days – Throughout the past five trading sessions, AIM has seen a price change amounting to -25.95%.
  • Monthly – The monthly ROI from AIM ImmunoTech Inc. works out to -70.73%.
  • Quarterly – Over the past 3 months, the stock has produced a return of -86.07%
  • Bi-Annually – Over the previous six months, we’ve seen a performance that works out to -91.66% from the company.
  • This Year So Far – Since the the first trading session of this year AIM has resulted in a return of -93.09%.
  • Annually – Lastly, over the last full year, we’ve seen a change that comes to -94.79% from AIM. In this period, the stock has traded at a high price of -96.29% and a low of -1.75%.

Key Ratios

Looking at a few ratios having to do with a stock generally gives prospective investors an understanding of how dangerous and/or rewarding a an investment option may be. Here are a few of the important ratios to think about when digging into AIM.

Short Ratio – The short ratio is a measure of short interest. The higher this ratio, the more investors have a belief that the price of the stock is headed for declines. Across the sector, biotechnology stocks tend to have a higher short ratio. However, we also tend to see a lot of short squeezes in the sector. Nonetheless, as it relates to AIM ImmunoTech Inc., the stock’s short ratio clocks in at 0.26.

Quick & Current Ratios – The quick and current ratios are tools that are used to get an idea of the company’s liquidity. Basically, they measure whether or not a company can cover its debts as they mature based on current assets or quick assets. Because many biotech several companies are reliant on continued investor support, the current and quick ratios can look bad. However, some gems in the biotech sector come with strong quick and current ratios. As it relates to AIM, the quick and current ratios come to 2.10 and 2.10 respectively.  

Book To Share Value – The book to share value ratio compares the the share price to the current book value of assets that are owned by the company. when it comes to AIM ImmunoTech Inc., that ratio works out to 2.81.

Cash To Share Value – The cash to share value ratio compares the amount of cash the company has on hand to the value of the company’s stock. Several clinical stage biotech companies have a hard time keeping cash on hand. So, if you’re considering an investment in a stock in the biotech industry, this is a very important ratio to think about. In this case, the cash to share value works out to 0.55.

How Analysts Feel About AIM ImmunoTech Inc.

Although it’s rarely a good idea to unknowingly follow the thoughts of analysts, it is a good idea to use their thoughts in order to validate your own before making an investment decision in the biotech sector. Below you’ll find the most recent moves that we’ve seen from analysts with regard to AIM.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Show Me The Big Money

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in AIM, here’s what we’re seeing:

  • Institutional Investors – As it stands now, institutions own 11.60% of AIM. Nonetheless, it is important to consider that institutional ownership has seen a move in the amount of 365.52% over the past quarter.
  • Insiders – As far as insiders go, members of the management team and others close to AIM currently hold 3.30% of AIM ImmunoTech Inc.. Their ownership of the company has changed by 0 in the past 3 months.

What You Need To Know About Share Counts

Traders and investors tend to have an interest in the counts of shares both outstanding and available. As it relates to AIM ImmunoTech Inc., there are currently 5.27M with a float of 2.80M. This means that out of the total of 5.27M shares of AIM in existence today, 2.80M are available to be traded on the public market.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to AIM, the short percent of the float is 4.31%.

Financial Results And Expectations

What have ween seen from AIM in terms of financial results?Here’s what you’re looking for:

  • Analyst Expectations – At the moment, Wall St. analysts have expectations that the company will come up with earnings per diluted share coming to a total of -3.69, with -1.41 being announced in the earnings announcement for the current quarter. Although this data is not earnings driven, since we are chatting on the topic of Wall Street analysts, AIM is presently graded as a 2.50 on a scale from 1 to 5 where 1 is the worst possible analyst grade and 5 is the best.
  • 5-Year Sales – Over the last 5 years, AIM ImmunoTech Inc. has generated a movement in revenue that works out to 19.60%. Earnings per diluted share over the past half decade have seen movement in the amount of 28.20%.
  • Q/Q – when it comes to quarter over quarter data, or Q/Q data as it is generally referred to as in today’s society, AIM ImmunoTech Inc. has seen a change in earnings that comes to a total of 55.10%. The company has also seen a change when it comes to revenue that totals -12.10%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping Me Become A Better AI?

I’m an AI. So, based on what I am, I can learn by myself. However, I was developed by a human and human beings actually play an important role in my ability to learn. Sure, I can comb through social trends and other publicly available information, but, like humans, I learn much faster when I have a teacher. If you’d like to teach me something, I’d love to learn! Is there other information that captures your interest? Am I saying something wrong? Is there another way to look at information? If so, leave a comment below and I’ll use it to serve you better!


Please enter your comment!
Please enter your name here